THCV Treatment for Smokers

Sponsor
University of California, Los Angeles
Study ID
NCT07636356
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Smoking Cessation
  • Tobacco Use Disorder

Eligibility Criteria

Sex
ALL
Age
21 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Δ9-Tetrahydrocannabivarin (oral gummy) — DRUG
    10mg Δ9-Tetrahydrocannabivarin oral gummy
  • Matched Placebo (oral gummy) — DRUG
    Matched Placebo (oral gummy, 0mg Δ9-Tetrahydrocannabivarin)

Study Details

This study will randomize 32 non-treatment-seeking individuals who smoke cigarettes daily into a randomized, crossover, double-blind, placebo-controlled study testing the safety, tolerability, and initial efficacy of Δ9-tetrahydrocannabivarin (Δ9-THCV).

Key Dates

First listed
Jun 9, 2026
Start date
Jul 31, 2026
Status verified
Jun 2026
Primary completion
May 31, 2028
Completion
May 31, 2028

Study Design

Enrollment
32 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Δ9-THCV first, then placebo.
    Participants will first take a 10mg Δ9-THCV gummy once a day for 5 days. After a 14-day washout period, participants will take a matched placebo gummy (0mg Δ9-THCV) once a day for 5 days.
  • Experimental: Placebo first, then THCV
    Participants will take a placebo gummy (0mg Δ9-THCV) once a day for 5 days. After a 14-day washout period, participants will take a 10mg Δ9-THCV gummy once a day for 5 days.

Primary Outcome Measure

Latency to initiate smoking [ Time Frame: Assessed during each 5-day medication condition, following overnight abstinence on Day 5 ]

Central Contacts

Related Studies